ROL vs ZYME · P/E 41, rev $3.39B vs rev $76.3M
Rollins Inc (ROL) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported ROL revenue for 2024-12-31 was $3.39B. Net income was $466.4M. Revenue was up 10.3% from 2023-12-31 to 2024-12-31. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
ROL currently screens at market cap $21.73B and trailing P/E 41.4. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the ROL and ZYME stock pages for the full models.
Not investment advice.